WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018081898) IMPROVEMENTS IN CD47 BLOCKADE THERAPY BY HDAC INHIBITORS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/081898 International Application No.: PCT/CA2017/051301
Publication Date: 11.05.2018 International Filing Date: 01.11.2017
IPC:
A61K 47/68 (2017.01) ,A61K 38/15 (2006.01) ,A61K 38/17 (2006.01) ,A61K 39/395 (2006.01) ,A61P 35/00 (2006.01) ,A61P 35/02 (2006.01) ,C07K 11/00 (2006.01) ,C07K 14/705 (2006.01) ,C07K 19/00 (2006.01) ,C07K 5/10 (2006.01)
Applicants: TRILLIUM THERAPEUTICS INC.[CA/CA]; 2488 Dunwin Drive Mississauga, Ontario L5L 1J9, CA
Inventors: LINDEROTH, Emma; CA
VILLER, Natasja Nielsen; CA
UGER, Robert Adam; CA
SLAVOVA-PETROVA, Penka Slavcheva; CA
Agent: BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.; Scotia Plaza, 40 King Street West, 40th Floor Toronto, Ontario M5H 3Y2, CA
Priority Data:
62/416,96803.11.2016US
Title (EN) IMPROVEMENTS IN CD47 BLOCKADE THERAPY BY HDAC INHIBITORS
(FR) AMÉLIORATIONS DE LA THÉRAPIE DE BLOCAGE DE CD47 PAR DES INHIBITEURS DE HDAC
Abstract: front page image
(EN) CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a histone deacetylase (HDAC) inhibitor. The anti-cancer effect of one drug enhances the anti-cancer effect of the other. Specific combinations include SIRPαFc as CD47 blockade drug, and one of depsipeptide and romidepsin as HDAC inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.
(FR) Des cellules de maladie CD47+, telles que des cellules cancéreuses, sont traitées à l'aide d'une combinaison d'un médicament de blocage de CD47 et d'un inhibiteur d'histone désacétylase (HDAC). L'effet anti-cancéreux d'un médicament améliore l'effet anti-cancéreux de l'autre. Des combinaisons spécifiques comprennent SIRPαFc en tant que médicament de blocage de CD47, et l'un parmi un depsipeptide et la romidepsine en tant qu'inhibiteur de HDAC. Ces combinaisons sont utiles en particulier pour traiter des cancers du sang, y compris des lymphomes, des leucémies et des myélomes.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)